Immunovant Inc To Discuss On Two New Indications For Batoclimab Call Transcript - Thomson StreetEvents

Immunovant Inc To Discuss On Two New Indications For Batoclimab Call Transcript

Immunovant Inc To Discuss On Two New Indications For Batoclimab Call Transcript - Thomson StreetEvents
Immunovant Inc To Discuss On Two New Indications For Batoclimab Call Transcript
Published Sep 07, 2022
22 pages (15923 words) — Published Sep 07, 2022
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of IMVT.OQ conference call or presentation 7-Sep-22 12:00pm GMT

  
Brief Excerpt:

...Operator Good morning. My name is Sarah, and I will serve as your conference call operator. As a reminder, this call is being recorded. Before we begin, I would like to remind everyone that today's conference call will include certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, for example, statements regarding the potential efficacy and safety of Immunovant's product candidate; expectations regarding the timing, design and results of its clinical trials, including the timing of future data readouts, the timing of interactions with regulatory agencies and expectations regarding Immunovant's cash runway. These forward-looking statements are not guarantees of future performance, are subject to various risks and uncertainties and assumptions, known or unknown, which could cause actual results to differ materially from those indicated or anticipated and speak only as of the date of this call....

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Immunovant Inc
Ticker
IMVT.OQ
Time
12:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Can you guys hear me okay?

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Super. Congrats on the progress. A couple on CIDP for me. You mentioned challenges finding patients with active CIDP. I just -- can you -- what's your level of concern just given others who are also pursuing active patients? And what's your sense of the screen-out rate you're expecting given the sort of extensive enrichment strategy? And then just the second question is, you mentioned this not being a one disease. Can you talk about your confidence in the sort of evidentiary level for the consistency of the pathophysiology here?

Table Of Contents

Immunovant Inc Initial Phase 1 Results Call Transcript – 2023-09-26 – US$ 54.00 – Edited Transcript of IMVT.OQ conference call or presentation 26-Sep-23 12:00pm GMT

Immunovant Inc Investor Day Transcript – 2022-09-28 – US$ 54.00 – Edited Transcript of IMVT.OQ corporate analyst meeting</ 28-Sep-22 3:15pm GMT

Immunovant Inc Q4 2022 Earnings Call Transcript – 2022-06-08 – US$ 54.00 – Edited Transcript of IMVT.OQ earnings conference call or presentation 8-Jun-22 12:00pm GMT

Immunovant Inc at UBS Global Healthcare Conference Transcript – 2022-05-23 – US$ 54.00 – Edited Transcript of IMVT.OQ presentation 23-May-22 5:15pm GMT

Immunovant Inc To Host R&D Day (Virtual) Transcript – 2022-03-30 – US$ 54.00 – Edited Transcript of IMVT.OQ corporate analyst meeting</ 30-Mar-22 1:00pm GMT

Immunovant Inc at JPMorgan Healthcare Conference (Virtual) Transcript – 2022-01-13 – US$ 54.00 – Edited Transcript of IMVT.OQ presentation 13-Jan-22 2:45pm GMT

Immunovant Inc To Discuss Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022 Call Transcript – 2022-01-05 – US$ 54.00 – Edited Transcript of IMVT.OQ conference call or presentation 5-Jan-22 1:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Immunovant Inc To Discuss On Two New Indications For Batoclimab Call Transcript" Sep 07, 2022. Alacra Store. May 18, 2024. <http://www.alacrastore.com/thomson-streetevents-transcripts/Immunovant-Inc-To-Discuss-On-Two-New-Indications-For-Batoclimab-Call-T15290117>
  
APA:
Thomson StreetEvents. (2022). Immunovant Inc To Discuss On Two New Indications For Batoclimab Call Transcript Sep 07, 2022. New York, NY: Alacra Store. Retrieved May 18, 2024 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Immunovant-Inc-To-Discuss-On-Two-New-Indications-For-Batoclimab-Call-T15290117>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.